Please login to the form below
Advent
This page shows the latest Advent news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca blocks take-private buyout of Sobi
The $7.6bn takeover of Swedish rare disease company Sobi by private equity group Advent International and Singapore’s wealth fund failed to convince the 90% of shareholders needed. ... The Board supported the public offer by Advent and GIC as we
Latest news
-
UK immunology biotech MiroBio launches with $34m fundraising
MiroBio’s Series A financing was co-led by Oxford Sciences Innovation and Samsara Biocapital, with Advent Life Sciences and SR One also joining the round. ... For the time being MiroBio has four directors – one apiece from each of its backers –
-
Hudson named Brandicourt’s successor as Sanofi’s CEO
deal and selling off its European generics business to private equity group Advent for $2.4bn, whilst implementing a big cost-reduction programme.
-
Gottlieb admonishes industry for clinical trial failings
Gottlieb – who is leaving the FDA next month and will be replaced on an interim basis by National Cancer Institute (NCI) director Ned Sharpless – says that the advent in precision medicine,
-
Pfizer’s flat sales focus investor attention on M&A
In the last few weeks Sanofi has sold its European generics business to Advent, GlaxoSmithKline divested its rare disease unit to start-up Orchard Therapeutics after buying Novartis out of a
-
P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit
In the last few weeks Sanofi has sold its European generics business to Advent, GlaxoSmithKline divested its rare disease unit to start-up Orchard Therapeutics after buying Novartis out of a
More from news
Approximately 3 fully matching, plus 95 partially matching documents found.
Latest Intelligence
-
Redefining medical communications in the age of omnichannel engagement
The adoption of digital engagement. The advent of omnichannel communications. What omnichannel is, as well as how to map out and execute an omnichannel journey, is subject to various definitions.
-
Powering creativity to work in harmony with science and data
He views the increasing product development in rare diseases and the advent of novel therapies as an ideal springboard for industry creativity.
-
Working together to achieve better patient pathways
The advent of new technology brings a really exciting opportunity to design pathways around patients and what’s right for them,” she said.
-
Unlocking the potential of data sharing
assessments. With the advent of increasingly sophisticated ways to process the data, scientists can now utilise platforms that share information instantly, enabling real-time assessments of patient safety and trial outcomes.
-
Charting patient pathways with precision for better healthcare
He sees the advent of integrated care systems in the NHS adding extra potency to mapping patient pathways and wants it underpinned by investment focused more on preventative measures to move
More from intelligence
Approximately 0 fully matching, plus 44 partially matching documents found.
Latest from PMHub
-
The power of influence in transforming women’s health
This provided an opportunity for natural remedies and non-pharmacological approaches. However, the lack of evidence and the advent of stricter legislation on claims limited their impact.
-
NAVIGATING 2022: THE FIVE CRITICAL SHIFTS PHARMA NEEDS TO EMBRACE
3. The shift to neighbourhood and place-based planning. With the advent of provider collaboratives and primary care networks working within ICSs, we are seeing the gradual dissolution of the boundaries
-
As HCPs Increasingly Expect Personalized Engagement, Pharmas Turn to Modular Intelligent Content. How Does This Work?
While personalized omnichannel communication is becoming the only truly acceptable option in brand communications, Life Sciences are deeply affected by the change. Compared to retail, the amounts of information to deliver alongside the key message
-
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
During the last two decades, the landscape for psoriasis treatment has exploded. The advent of biologic therapies at the turn of the millennium and the subsequent development of T-cell
-
Out Of Office: The New Normal for Ad Agencies
The advent of online approval and asset management. The decline of the salesforce.
More from PMHub
Approximately 0 fully matching, plus 20 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
